Study highlights the significant enhancement in predicting common diseases like heart disease, diabetes, Alzheimer’s, and prostate cancer by integrating polygenic risk scores (PRSs) and gut microbiome scores with conventional risk factors, showcasing the potential of multiomic approaches in personalized medicine.
23andMe Scores FDA Clearance for Novel Cancer Immunotherapy Targeting NK Cells
What You Should Know: – 23andMe Holding Co. (Nasdaq: ME), a genetics and biopharmaceutical company, announced The U.S. Food and Drug Administration (FDA) has cleared